The Stargardt Disease market is expected to surge due to the disease's increasing prevalence and awareness during the ...

SpliceBio, a clinical-stage genetic medicines company, announced that it has dosed the first patient in the phase ½ Astra ...

marking the final stage of the Phase 1 dose-escalation study. Ocugen’s GARDian trial aims to offer a beacon of hope for patients with Stargardt disease by potentially providing a viable and long ...

The biotech’s lead program is in preclinical development for Stargardt disease, a rare eye disorder caused by multiple genetic mutations. Kathy Bleitz suffers from a condition called Stargardt ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

BARCELONA, Spain, March 13, 2025 /PRNewswire/ -- SpliceBio, a clinical-stage genetic medicines ... for the treatment of Stargardt disease. Stargardt disease is an inherited retinal disorder ...

AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), announces the publication of their preclinical ...

Stargardt disease is an inherited retinal disorder caused ... About SpliceBioSpliceBio is a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused ...

MILAN, March 31, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology ... of their preclinical research in Stargardt’s disease in Science Advances, a ...